Clinical Research Directory
Browse clinical research sites, groups, and studies.
Lanreotide In Polycystic Kidney Disease Study
Sponsor: Assistance Publique - Hôpitaux de Paris
Summary
LIPS study (Lanreotide In Polycystic kidney disease Study) is a prospective randomized double blind placebo controlled study. The main objective is to prove that lanreotide, a somatostatin analog, is able to reduce the glomerular filtration rate decline over 3 years by at least 30%. Cardiovascular outcomes, blood pressure, quality of life and safety are among the secondary outcomes. The study, which will include 180 ADPKD patients, is scheduled to start in early 2014. An equal number of patients with chronic kidney disease stage 2 (90 patients with GFR 89 to 60 ml/mn/1.73 m2) and chronic kidney disease stage 3 (90 patients with GFR 59 to 30 ml/mn/1.73 m2) will be included. The primary endpoint (GFR decline) will be assessed by repeated measures, in the overall population as well as in the two GFR stratus.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
159
Start Date
2014-09-19
Completion Date
2019-07-31
Last Updated
2026-04-08
Healthy Volunteers
No
Interventions
Lanreotide
120 mg, subcutaneously, once every 4 weeks
saline
0,5 ml, subcutaneously, once every 4 weeks
Locations (1)
Necker hospital
Paris, France